000
| 02365cam 2200337za 4500 |
---|
001 | 9.852909 |
---|
003 | CaOODSP |
---|
005 | 20221107154710 |
---|
007 | cr ||||||||||| |
---|
008 | 180305s2018 onc ob f000 0 eng d |
---|
020 | |a9780660255569 |
---|
040 | |aCaOODSP|beng |
---|
043 | |an-cn--- |
---|
086 | 1 |aHP40-211/2018E-PDF |
---|
245 | 00|aLiterature review on individuals with neurologic or neurodevelopment conditions and risk of serious influenza-related complications |h[electronic resource]. |
---|
246 | 1 |iAt head of title; |aAdvisory committee review, National Advisory Committee on Immunization (NACI) |
---|
260 | |a[Ottawa] : |bPublic Health Agency of Canada,|c2018. |
---|
300 | |a148 p. |
---|
500 | |aIssued also in French under title: Revue de la littérature portant sur les personnes atteintes de troubles neurologiques ou du développement neurologique et sur le risque de présenter de graves complications liées à la grippe |
---|
500 | |aCover title. |
---|
500 | |a"Publication date: May 2018." |
---|
500 | |aPrepared by: L. Zhao ... [et al.]. Cf. Acknowledgements. |
---|
504 | |aIncludes bibliographical references (p. 34-43). |
---|
520 | |a“Neurologic or neurodevelopment conditions (NNCs) account for a substantial burden of disease globally and in Canada. Based on preliminary reviews of evidence, NACI has included children (since the 2015−2016 influenza season) and adults (since the 2016−2017 influenza season) with NNCs among the high-risk groups for whom influenza vaccination is particularly recommended. The present literature review was conducted to provide a rapid synthesis of the evidence to further inform NACI’s assessment regarding the inclusion of individuals with NNCs as a high-risk group for influenza-related complications”--Executive summary, p. 4. |
---|
692 | 07|2gccst|aImmunization |
---|
692 | 07|2gccst|aInfluenza |
---|
693 | 4|aNervous system--Diseases |
---|
710 | 1 |aCanada. |bNational Advisory Committee on Immunization. |
---|
710 | 2 |aPublic Health Agency of Canada. |
---|
775 | 08|tRevue de la littérature portant sur les personnes atteintes de troubles neurologiques ou du développement neurologique et sur le risque de présenter de graves complications liées à la grippe |w(CaOODSP)9.852910 |
---|
856 | 40|qPDF|s1.44 MB|uhttps://publications.gc.ca/collections/collection_2018/aspc-phac/HP40-211-2018-eng.pdf |
---|